<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534787/" ref="ordinalpos=1175&amp;ncbi_uid=5724663&amp;link_uid=PMC3534787" image-link="/pmc/articles/PMC3534787/figure/F5/" class="imagepopup">Figure 5. Vorinostat dampens cell survival <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: Vorinostat, an HDAC Inhibitor Attenuates Epidermoid Squamous Cell Carcinoma Growth by Dampening mTOR <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> in a Human Xenograft Murine Model. </a></div><br /><div class="p4l_captionBody">(A &amp; B) WB and relative densitometry analysis for AKT/mTOR signaling markers. p-AKT1/2/3 Thr308 (*p=0.004), p-AKT1/2/3 ser473 (*p=0.001), AKT1/2/3 (*p=0.19) significantly reduced in vorinostat treatment group of mice. (C&amp;D) WB and densitometry analysis of p-mTOR (*P=0.04) and total m-TOR (P=0.15) in vorinostat treated group represent significant reduction of p-mTOR level. (E&amp;F) WB and densitometry analysis of p-mTOR (*P=0.027) and total mTOR (*P=0.009) levels in vorinostat (2Î¼M) treated A431 cells. (G&amp;H) WB and relative densitometry analysis mTOR signaling proteins, p-p70S6 kinase (**P=0.001), p70S6 kinase (P=0.976), p-S6 ribosomal protein (**P=0.004), S6 ribosomal protein (**P=0.005), p-4E-BP1 (**p=0.003) and 4E-BP1 (*p=0.033).</div></div>